Loading...
Therapeutics Acquisition Corp.
RACA•NASDAQ
Financial Services
Shell Companies
$10.27
$0.24(2.44%)
U.S. Market opens in 6h 34mTherapeutics Acquisition Corp. (RACA) AI-Powered Stock Analysis
See how Therapeutics Acquisition Corp. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerTherapeutics Acquisition Corp. (RACA) Stock Overall Grade
Therapeutics Acquisition Corp.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Therapeutics Acquisition Corp.'s overall stock rating.
Forecast
C+Score
52/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Therapeutics Acquisition Corp. (RACA) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 52/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Therapeutics Acquisition Corp. stock grade, including financials, comparisons, and forecasts.